Medtech Funding and Regulatory News: FDA Clearances, a CE Mark, and New Capital

FDA clearances for surgical robotics, a CE Mark for a next-generation mitral valve, fresh financing for dental, women’s health, and aortic companies, and several first-patient milestones marked another active week in the LSI Alumni community.

The updates span robotic surgery, cardiovascular devices, pulmonary medicine, neurotechnology, dental care, imaging, and women’s health, and together they show how emerging companies advance from development into clinical use.

For medtech investors, milestones like these are early indicators of clinical validation, regulatory execution, leadership strength, and financing momentum. Compass AI tracks the same signals across the private medtech market.

Apreo Health Treats First Patient in BREATHE-3  

Apreo Health treated the first patient in its BREATHE-3 study at Houston Methodist.

The study evaluates the BREATHE Airway Scaffold, a bronchoscopically delivered, self-expanding implant designed to relieve lung hyperinflation in people with emphysema who remain symptomatic despite optimal medical management.

First treatment moves Apreo’s minimally invasive approach to severe emphysema further into clinical evaluation.

AQUAPASS Appoints Michael Tajima as COO  

AQUAPASS named Michael Tajima chief operating officer. Tajima brings 16 years of medical device leadership across product development, evidence generation, commercialization, globalization, and organizational scaling, most recently leading strategy at Paragonix Technologies.

His operating experience supports AQUAPASS as it enters its next phase of development.

Axoft Introduces an Optically Invisible Soft Material

Axoft introduced Fleuron Water Invisible Soft Elastomer (WISE), a UV-curable material engineered to match water’s refractive index, which makes it optically invisible when submerged.

Because it is extremely soft, flexible, and waterproof, the material reduces optical distortion and improves image sharpness and resolution in aqueous samples.

It is a good example of materials science opening new possibilities in imaging and other medical applications.

Calla Lily Clinical Care Adds Mark Lubkeman to Its Board  

Calla Lily Clinical Care appointed Mark Lubkeman to its board of directors. Lubkeman has 35 years of experience across biopharma and medtech, including serving as COO of IntraBio, where he led its U.S. product launch, and heading Boston Consulting Group’s Global Biopharma business.

His commercialization and corporate strategy experience adds depth as the company expands.

FDA Clears PERLA TL for the eCential Robotics Spine Platform  

eCential Robotics and Spineart received FDA clearance for the PERLA TL application on the eCential Op.n Navigation and Robotic-Assisted Platform.

Surgeons can now use integrated navigation and robotics to guide implant placement in both open and minimally invasive spine procedures.

 The clearance extends the platform’s regulatory footprint and its role in spine surgery.

HighLife Receives CE Mark for the Clarity Mitral Valve  

HighLife received CE Mark approval for its Clarity Mitral Heart Valve, used with the HighLife Transcatheter Mitral Valve Replacement (TMVR) System.

Clarity is the next generation of the company’s TMVR platform, designed to reduce further the risk of left ventricular outflow tract (LVOT) obstruction while keeping the platform’s transfemoral valve-in-ring design.

Lupin Dental Closes €15M Series A  

Lupin Dental closed a €15M Series A led by Fynveur, which invested €10M, with continued support from existing shareholders and new private investors. A loan from Bpifrance complements the round.

The funding supports Lupin’s next phase of growth as it works to change how dental care is delivered.

The round fits a broader pattern in Medtech funding: investors are backing companies with a clear clinical and commercial path.

Materna Medical completed the final close of its oversubscribed Series B3, adding new investors Portfolia and Dalton Investments alongside returning investors including GLIN, Harbright Ventures, Women’s Venture Capital Fund, and Houston Angel Network.

The financing strengthens Materna’s investor base as it approaches its next product launch.

It is also another sign of growing investment in women’s health technologies that address specific unmet clinical needs.

Noah Medical Integrates Galaxy with GE HealthCare C-Arms  

Noah Medical announced that its Galaxy System can now integrate with GE HealthCare’s OEC C-arm portfolio.

The new Galaxy II software works with the OEC 3D mobile cone-beam CT and the OEC Elite CFD, OEC 9900, and OEC 9800 C-arms, supporting image-guided, robotic-assisted bronchoscopy for minimally invasive lung diagnosis.

Tighter integration with existing imaging equipment can make robotic bronchoscopy easier for hospitals to adopt.

Paradromics Gains FDA Approval for Broader BCI Connectivity 

Paradromics received an FDA letter allowing its brain-computer interface (BCI) to connect with a broader range of computing devices.

Instead of relying on a company-supplied computer, trial participants and future users can pair the BCI with personal devices they already use.

It addresses a practical adoption question for neurotechnology: how well new interfaces fit into patients’ existing technology.

Pulnovo Medical Begins Enrollment in PULSE-LHD 

Pulnovo Medical enrolled the first two patients in its PULSE-LHD trial at Henry Ford Hospital in Detroit.

The multicenter, randomized, placebo-procedure-controlled IDE study will assess pulmonary artery denervation in patients with combined pre- and post-capillary pulmonary hypertension associated with left heart disease.

Enrollment marks the start of the program’s U.S. clinical evaluation.

Qaelon Medical Adds Dr. Rick Estape to Its Scientific Advisory Board  

Qaelon Medical appointed Ricardo “Rick” Estape, MD, to its Scientific Advisory Board. Dr. Estape has performed more than 11,000 robotic procedures across benign and oncologic gynecology.

His perspective on insufflation, visualization, and workflow in robotic gynecologic surgery supports the company’s product development.

Samay Secures Canadian Patent for Sylvee 

Samay was granted its 23rd patent, covering a core component of Sylvee: its acoustic resonance technology, which reads changes in lung function from sound patterns in the body.

The Canadian patent strengthens Samay’s IP position in a market with a heavy burden of chronic obstructive pulmonary disease (COPD).

For investors, a growing patent estate is a key measure of long-term defensibility.

Shape Memory Medical Raises Convertible Note Financing 

Shape Memory Medical closed a convertible note financing with new investors August Global Partners and Taiwania Capital.

Proceeds support its aortic portfolio, including follow-up and data collection in the AAA-SHAPE pivotal trial and progress in the FLAGSHIP feasibility trial.

It is another case of investors backing companies through clinical development toward regulatory milestones.

Venous Stent Completes First-in-Human ALTA Implant  

 Venous Stent completed the first-in-human implantation of its ALTA Venous Stent, moving the next-generation device for iliac vein stenting from preclinical work into patients.

First-in-human data is an early indicator of clinical performance.

Virtual Incision Expands MIRA Indication to Benign Hysterectomy 

Virtual Incision received FDA 510(k) clearance for the MIRA Surgical System in benign hysterectomy, based on a prospective IDE study conducted by five surgeons at three U.S. hospitals.

The study showed the system’s safety and performance in these procedures, and the clearance broadens MIRA’s clinical applications.

What This Week Signals for Medtech 

Regulatory progress is opening commercial doors.

FDA clearances, a CE Mark, and trial milestones are moving robotics, cardiovascular, pulmonary, neurotechnology, and women’s health technologies toward wider clinical use.

Capital is following demonstrated progress. 

This week’s financings went to companies with clinical evidence, regulatory execution, and a credible commercialization plan. Follow the latest medtech funding news. 

Strategic positioning matters.  

Leadership hires, technology integrations, patents, and clinical partnerships all shape how emerging companies position themselves for growth and potential M&A.

For medtech investors and acquirers, these signals show where clinical validation is advancing and which technologies may soon become strategically relevant.

Compass AI brings company, financing, clinical, regulatory, and market signals together so executives can see what is happening across the ecosystem and where it is heading. Book a Compass AI demo to track these companies in one place.

Key Takeaways 

• Clinical programs advanced in robotic surgery, cardiovascular devices, pulmonary medicine, neurotechnology, imaging, dental care, and women’s health.
• FDA clearances, a CE Mark, and trial progress are moving technologies toward commercialization.
• Financing is going to companies that are generating data and hitting milestones.
• Executive appointments, integrations, and IP are strengthening companies for their next stage.
• Today’s clinical and regulatory milestones are early indicators of tomorrow’s deal opportunities.

This week’s LSI Alumni news shows emerging medtech companies moving steadily from development to clinical use and commercialization. For investors and acquirers, milestones like these are the clearest guide to where traction is building.